[Remote] Medical Director, GU Oncology at Natera

Remote

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Healthcare, Medical Devices, BiotechnologyIndustries

Skills

Key technologies and capabilities for this role

GU cancersbladder cancerkidney cancerclinical developmentmedical educationscientific communicationclinical trial designdata analysisoncology expertisemedical advocacy

Questions & Answers

Common questions about this position

Is this position remote or does it require office work?

The position is remote with approximately 50% domestic and international travel.

What is the salary for the Medical Director role?

This information is not specified in the job description.

What qualifications and experience are required for this role?

Candidates must have an M.D. or D.O. degree with board certification in Oncology and at least 5 years of experience in oncology. A background in clinical research and development is preferred, along with clinical experience in GU cancer.

What kind of collaboration is involved in this role?

The role involves working effectively with cross-functional teams including research, development, commercial, and medical affairs, as well as coordinating with internal and external stakeholders.

What makes a strong candidate for this Medical Director position?

Strong candidates will have GU cancer expertise (especially bladder and kidney), broad oncology knowledge across histologies, and the ability to collaborate cross-functionally while quickly learning Natera's technology.

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Austin, TexasHeadquarters

2004Year Founded

$149.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

1,001-5,000Employees

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.

New Prospera Heart features may face slow adoption by healthcare providers.

Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.

Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.

Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.

AI integration enhances accuracy and speed of Natera's cfDNA analysis.

Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI

Try Jobo Free